Table 2. Genetic polymorphisms of eNOS and Cav-1 genes in association with LAA stroke risk.
| Gene and SNP a | Cases (%) | CTLs (%) | cOR (95% CI)b | aOR (95% CI)c | aOR (95% CI)d |
|---|---|---|---|---|---|
| e-NOS G894T (rs1799983, Glu/Asp) | |||||
| GG | 151 (65.9) | 185 (76.1) | 1.00 (Ref)e | 1.00 (Ref) | 1.00 (Ref.) |
| GT | 62 (27.1) | 51 (21.0) | 1.49 (0.97–2.29) | 1.52 (0.93–2.46) | 1.72 (1.09–2.75)* |
| TT | 16 (7.0) | 7 (2.9) | 2.80 (1.12–6.98)* | 3.45 (1.25–9.55)* | |
| G allele | 364 (79.5) | 421 (86.6) | 1.00 (Ref) | ||
| T allele | 94 (20.5) | 65 (13.4) | 1.67 (1.18–2.36)* | ||
| Cav-1 G14713A (rs3807987) | |||||
| GG | 138 (60.3) | 174 (71.6) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref.) |
| GA | 75 (32.7) | 60 (24.7) | 1.57 (1.05–2.36)* | 1.71 (1.08–2.69)* | 1.79 (1.16–2.74)** |
| AA | 16 (7.0) | 9 (3.7) | 2.24 (0.96–5.23) | 2.34 (0.90–5.92) | |
| G allele | 351 (76.6) | 408 (84.0) | 1.00 (Ref) | ||
| A allele | 107 (23.4) | 78 (16.0) | 1.59 (1.15–2.21)* | ||
| Cav-1 T29107A (rs7804372) | |||||
| TT | 128 (55.9) | 167 (68.7) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref.) |
| TA | 82 (35.8) | 65 (26.7) | 1.65 (1.11–2.45)* | 1.58 (1.01–2.45)* | 1.61 (1.06–2.43)* |
| AA | 19 (8.3) | 11 (4.6) | 2.25 (1.04–4.90)* | 1.70 (0.71–4.06) | |
| T allele | 338 (73.8) | 399 (82.1) | 1.00 (Ref) | ||
| A allele | 120 (26.2) | 87 (17.9) | 1.63 (1.19–2.22)* | ||
a The ‘rs’ number shown is the National Center for Biotechnology Information dbSNP cluster ID for each SNP.
b cOR, crude odd ratio;
c aOR, statistical analysis was calculated by unconditional logistic regression and adjusted for age, gender, alcohol drinking, cigarette smoking, and disease status of diabetes mellitus, gout, hypertension, and hypercholesterolemia.
d In these regression models, heterozygous and homozygous variants were grouped together and compared to the homozygous wild-type variant.
e Ref, reference group.
* P < 0.05,
** P < 0.01.